… In addition, other novel PDE inhibitors are in different phases of clinical trials. The current …
various PDEs and the potential application of selective PDE inhibitors in the treatment of COPD …

… of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-…
and COPD patients, as well as in experimental rodent models of pulmonary inflammation. …

… selective PDE4 inhibitor like roflumilast has a better therapeutic index that a PDE4D selective
inhibitor … Inhaled PDE4 inhibitors offer an intriguing new class of treatment for inflammatory …

… Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung
diseases: dualselective phosphodiesterase inhibitors and novel combination therapies. Handb …

… Marketed PDE inhibitors in pulmonary diseases. This table … evidence for marketed PDE
inhibitors in lung diseases. Trade … a selective PDE inhibitor with the highest affinities to PDE 4A1 (…

… pulmonary disease (COPD). Herein, we describe a drug discovery program aiming at the
identification of novel classes of potent PDE4 inhibitors … be highly selective inhibitors for PDE4 (…

… that inhibition of specific PDE isoforms can improve therapy of obstructive lung diseases
by … therein should then provide impetus to develop new drugs with PDE isoform selectivity. …

… selective PDE4 inhibitors may be potential treatment options for chronic respiratory diseases
apart from COPD … Moreover, the novel oral PDE4 inhibitor MEM1414 has been tested for its …

… PDE inhibitor to enter the market and its use has exclusively been approved for the treatment
of chronic obstructive pulmonary disease (COPD… reason why selective PDE inhibitors are of …

… that PDE4 inhibition targets selective … treatment to a COPD subgroup [22], while ensifentrine
has the exciting potential of a novel bronchodilator mechanism that improves lung function …